Psychosis-Pipeline Review, H1 2015

Psychosis-Pipeline Review, H1 2015

  • Products Id :- GMDHC6628IDB
  • |
  • Pages: 52
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Psychosis-Pipeline Review, H1 2015


Global Markets Direct's, 'Psychosis-Pipeline Review, H1 2015', provides an overview of the Psychosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Psychosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psychosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Psychosis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Psychosis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Psychosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Psychosis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Psychosis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Psychosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Psychosis Overview 6

Therapeutics Development 7

Pipeline Products for Psychosis-Overview 7

Pipeline Products for Psychosis-Comparative Analysis 8

Psychosis-Therapeutics under Development by Companies 9

Psychosis-Therapeutics under Investigation by Universities/Institutes 10

Psychosis-Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Unknown Stage Products 14

Psychosis-Products under Development by Companies 15

Psychosis-Products under Investigation by Universities/Institutes 16

Psychosis-Companies Involved in Therapeutics Development 17

Acadia Pharmaceuticals Inc. 17

Evotec AG 18

Heptares Therapeutics Ltd. 19

Newron Pharmaceuticals S.p.A. 20

Reviva Pharmaceuticals Inc. 21

Sumitomo Dainippon Pharma Co., Ltd. 22

Psychosis-Therapeutics Assessment 23

Assessment by Monotherapy Products 23

Assessment by Target 24

Assessment by Mechanism of Action 26

Assessment by Route of Administration 28

Assessment by Molecule Type 29

Drug Profiles 30

Drug to Agonize Muscarinic M1/M4 Receptors for Psychosis and Cognitive Impairment-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Drug to Agonize Muscarinic M4 Receptors for Psychosis-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

NW-3509-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

pimavanserin tartrate-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

RP-5063-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Small Molecule to Inhibit PDE10a for Schizophrenia and Psychosis-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Small Molecules to Activate Sigma Receptor for CNS Disorders-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Small Molecules to Agonize M1/M4 Muscarinic Acetylcholine Receptors for Psychosis-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Psychosis-Recent Pipeline Updates 39

Psychosis-Dormant Projects 45

Psychosis-Discontinued Products 46

Psychosis-Product Development Milestones 47

Featured News & Press Releases 47

Nov 17, 2014: Heptares First-In-Class Selective Muscarinic Agonists Chosen As One Of Top Neuroscience Projects To Watch 47

Sep 02, 2014: Acadia Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID (Pimavanserin) for Parkinson's Disease Psychosis 47

Aug 28, 2014: ACADIA Pharmaceuticals Announces Trade Name NUPLAZID for Pimavanserin 48

Apr 14, 2010: Joseph Friedman To Present Data From ACADIA's First Phase III Trial With Pimavanserin For PDP At 62nd American Academy Of Neurology Annual Meeting 48

Sep 01, 2009: ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis 49

May 06, 2009: ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis 50

Jun 11, 2007: ACADIA Pharmaceuticals Initiates Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis 50

Appendix 51

Methodology 51

Coverage 51

Secondary Research 51

Primary Research 51

Expert Panel Validation 51

Contact Us 51

Disclaimer 52

List of Tables

Number of Products under Development for Psychosis, H1 2015 7

Number of Products under Development for Psychosis-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Number of Products under Investigation by Universities/Institutes, H1 2015 10

Comparative Analysis by Late Stage Development, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Development, H1 2015 13

Comparative Analysis by Unknown Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Products under Investigation by Universities/Institutes, H1 2015 16

Psychosis-Pipeline by Acadia Pharmaceuticals Inc., H1 2015 17

Psychosis-Pipeline by Evotec AG, H1 2015 18

Psychosis-Pipeline by Heptares Therapeutics Ltd., H1 2015 19

Psychosis-Pipeline by Newron Pharmaceuticals S.p.A., H1 2015 20

Psychosis-Pipeline by Reviva Pharmaceuticals Inc., H1 2015 21

Psychosis-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 22

Assessment by Monotherapy Products, H1 2015 23

Number of Products by Stage and Target, H1 2015 25

Number of Products by Stage and Mechanism of Action, H1 2015 27

Number of Products by Stage and Route of Administration, H1 2015 28

Number of Products by Stage and Molecule Type, H1 2015 29

Psychosis Therapeutics-Recent Pipeline Updates, H1 2015 39

Psychosis-Dormant Projects, H1 2015 45

Psychosis-Discontinued Products, H1 2015 46

List of Figures

Number of Products under Development for Psychosis, H1 2015 7

Number of Products under Development for Psychosis-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Early Stage Products, H1 2015 13

Assessment by Monotherapy Products, H1 2015 23

Number of Products by Top 10 Targets, H1 2015 24

Number of Products by Stage and Top 10 Targets, H1 2015 24

Number of Products by Top 10 Mechanism of Actions, H1 2015 26

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 26

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 28

Number of Products by Stage and Top 10 Molecule Types, H1 2015 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Acadia Pharmaceuticals Inc.

Evotec AG

Heptares Therapeutics Ltd.

Newron Pharmaceuticals S.p.A.

Reviva Pharmaceuticals Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Psychosis Therapeutic Products under Development, Key Players in Psychosis Therapeutics, Psychosis Pipeline Overview, Psychosis Pipeline, Psychosis Pipeline Assessment

select a license

Single User License
USD 2000 INR 136600
Site License
USD 4000 INR 273200
Corporate User License
USD 6000 INR 409800



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]